[
  {
    "ts": null,
    "headline": "Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time",
    "summary": "Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend.",
    "url": "https://finnhub.io/api/news?id=e7290375aef076c37ddcaf65fca4a382dacd8f4c4862954ad40e28844e859761",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772030400,
      "headline": "Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time",
      "id": 139210650,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend.",
      "url": "https://finnhub.io/api/news?id=e7290375aef076c37ddcaf65fca4a382dacd8f4c4862954ad40e28844e859761"
    }
  },
  {
    "ts": null,
    "headline": "Is Abbott Laboratories Stock Underperforming the Nasdaq?",
    "summary": "Abbott Laboratories has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=9b1605abd15c4c4dd82e584dabbb0467b183822a26ecda45b85ea603a9d25011",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772028675,
      "headline": "Is Abbott Laboratories Stock Underperforming the Nasdaq?",
      "id": 139215545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=9b1605abd15c4c4dd82e584dabbb0467b183822a26ecda45b85ea603a9d25011"
    }
  },
  {
    "ts": null,
    "headline": "How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects",
    "summary": "Abbott Laboratories is back in focus after several research houses reset their price targets, with some cuts in the US$5 to US$29 range and at least one target lifted into the mid US$150s. Those moves reflect a split narrative, where some analysts point to execution risk and slower earnings translation. Others highlight Abbott’s broad healthcare portfolio and an upgrade that leans on its longer term positioning. As you read on, you will see how these shifting price targets feed into an...",
    "url": "https://finnhub.io/api/news?id=e35ea7f46a486432fc552f67fff5e475a14e1d7353b5d105a7ae8c43ff1c58d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772014442,
      "headline": "How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects",
      "id": 139206500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories is back in focus after several research houses reset their price targets, with some cuts in the US$5 to US$29 range and at least one target lifted into the mid US$150s. Those moves reflect a split narrative, where some analysts point to execution risk and slower earnings translation. Others highlight Abbott’s broad healthcare portfolio and an upgrade that leans on its longer term positioning. As you read on, you will see how these shifting price targets feed into an...",
      "url": "https://finnhub.io/api/news?id=e35ea7f46a486432fc552f67fff5e475a14e1d7353b5d105a7ae8c43ff1c58d1"
    }
  }
]